US5260282A - Saliva substitute - Google Patents

Saliva substitute Download PDF

Info

Publication number
US5260282A
US5260282A US07/864,395 US86439592A US5260282A US 5260282 A US5260282 A US 5260282A US 86439592 A US86439592 A US 86439592A US 5260282 A US5260282 A US 5260282A
Authority
US
United States
Prior art keywords
linseed
water
composition
aqueous solution
mpa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/864,395
Other languages
English (en)
Inventor
Rolf Attstrom
Per O. Glantz
Hakan Hakansson
Kare Larsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandberg Development AB
Original Assignee
Camurus AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Camurus AB filed Critical Camurus AB
Assigned to CAMURUS AB, A CORPORATION OF SWEDEN reassignment CAMURUS AB, A CORPORATION OF SWEDEN ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: ATTSTROM, ROLF, GLANTZ, PER-OLOF, HAKANSSON, HAKAN, LARSSON, KARE
Application granted granted Critical
Publication of US5260282A publication Critical patent/US5260282A/en
Assigned to GS DEVELOPMENT AB reassignment GS DEVELOPMENT AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CAMURUS AB
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the field of saliva substitutes. More specifically it has been shown that a certain type of polysaccharides possess such properties that they can work as saliva substitutes for individuals with developed reduced salivary secretion. Thus, the invention relates to a novel saliva substitute, to a process for the preparation thereof, and to a specific use of the same as a carrier or vehicle in connection with pharmaceuticals.
  • the reduced secretion of saliva causes subjective symptoms in the form of burning tongue, mouth, pharynx and esophagus and sensitivity to spicy food and beverages. Some individuals are also affected as to speech and swallowing. Objectively dryness of the mouth often causes caries and periodontitis, which are difficult to treat since the reduced secretion of saliva results in a more pronounced retention of bacteria in the oral cavity and on the teeth. The resistance of the mucosa against colonization of bacteria is reduced and especially fungal infections are common in connection with individuals with xerostomia. Furthermore, people carrying so called plate prosthesis often have great problems with the retention of the prosthesis as well as infection of the mucosa as consequences of the dryness of the mouth.
  • the salivary glands of the mouth normally produce around 1-1.5 1 of saliva per 24 hours, and it must be considered unrealistic to utilize a saliva substitute which has to be taken in such a volume per 24 hours. Therefore, said agent has to possess such retention properties that it is retained and lubricates the teeth and mucosas for a relatively long time after a dosage has been taken. Furthermore, the preparation has to be swallowable so as to reduce the problems or symptoms in the pharynx and the esophagus.
  • novel saliva substitutes are provided which eliminate or at least significantly reduce the disadvantages of the previously known agents and which fulfil the requirements for agents of this type.
  • the present invention is based on the discovery that polysaccharides of the types which are present in linseed possess a very unusual combination of rheological and surface-chemical properties, which make them extremely suitable for the application defined above. That is, the present invention relates to a saliva substitute, the characteristic feature of which is that it comprises water-soluble linseed polysaccharides.
  • those polysaccharides which are intended to be used as the main ingredient of the saliva substitute according to the invention are of the type that is obtainable by a simple extraction in water of said polysaccharides directly from linseed.
  • One way of obtaining said polysaccharides which will be described more in detail below, therefore is to directly dissolve the polysaccharides from linseed by means of water, but of course the invention is not limited to such an embodiment.
  • Any polysaccharide fraction having the corresponding or essentially similar composition and obtainable in any other way, even synthetically, is thus within the scope of the invention, as a corresponding effect should be obtainable thereby.
  • solvents e.g. ethanol (for instance up to 70% of ethanol in water) or even completely other solvents than water, provided that said combinations or other solvents dissolve essentially the same polysaccharides as water.
  • ethanol for instance up to 70% of ethanol in water
  • a disadvantage of such an extraction is that it will then be necessary to evaporate or strip the "extra" solvent(s) utilized and then optionally redissolve the extract in water before it can be used as a saliva substitute, provided the used solvent is not directly physiologically acceptable.
  • the "water-soluble linseed polysaccharides" according to the invention may be obtained by a simple dissolution or extraction from linseed in water of approximately room temperature.
  • the invention is not limited to said water temperature, as a dissolution at a lower or higher temperature should give similar results.
  • the experiments made seem to indicate that the exact composition of the polysaccharide fraction is not especially critical.
  • merely in Sweden there are some tens of linseed varieties, and all those varieties should be useful according to the invention.
  • a preferable saliva substitute according to the present invention is therefore characterized in that it is present in the form of an aqueous solution of the above-mentioned linseed polysaccharides, which solution has a viscosity within the range of 1-30 mPa.s (cP), it of course being understood that said aqueous solution is physiologically acceptable.
  • viscosity has been determined by a measurement in a Bohlin VOR-rheometer in the conventional way (sheer rate 10 s -1 )
  • a preferable viscosity range is 1-20 mPa.s, the range of 2-10 mPa.s being especially preferable.
  • one percent by weight of the polysaccharide fraction in water may vary as to viscosity within the range of from about 0.02 to about 0.28 Pas.
  • an adjustment of said viscosity may be made merely by an adjustment of the concentration of the linseed polysaccharides in the aqueous solution. This should mean that all linseed varieties are useful as starting materials for the saliva substitute according to the invention.
  • aqueous solution a pure water solution of the linseed polysaccharides is not necessarily referred to.
  • Any aqueous liquid or solution which is acceptable to the human body should be useful, which inter alia may mean water containing such inorganic salts which are present in common saliva. Sodium chloride and potassium bicarbonate can be mentioned as examples thereof.
  • the concentrations of said salts may then preferably be up to those concentrations which are present in natural or common saliva.
  • the total contents of salts in common saliva is of the order of magnitude of 3 mg per ml of water (saliva), which should thus represent a preferable upper limit as to the total salts content.
  • concentration of salts in common saliva is of the order of magnitude of 3 mg per ml of water (saliva), which should thus represent a preferable upper limit as to the total salts content.
  • a preferable embodiment of the saliva substitute according to the invention is a substitute wherein the linseed polysaccharides have been obtained by an extraction from linseed with water or a salt solution of the type referred to above.
  • the above-mentioned extraction is performed at a temperature around room temperature.
  • the aqueous solution additionally contains one or more flavoring agents to have a more pleasant taste and/or to mask some salty taste.
  • One preferable flavoring agent is xylitol.
  • Another example of a flavoring agent is a fruit juice, e.g. lemon juice.
  • it can suitably contain a conventional preservative.
  • the aqueous solution contains one or more therapeutically active agents, such as agents against fungal, viral and/or bacterial diseases, to have a concurrent treatment against such diseases.
  • a preferable additive is cortico steroids, which are useful for instance against inflammatory mouth sores.
  • Other preferable additives may be xylitol and fluorine compounds (both being favorable to the teeth as is known per se).
  • Sodium fluoride is one example of a fluoride for such a use.
  • Said fluorine compounds can generally be used in amounts of 0.5-1.5, preferably 0.8-1.2 mg/liter.
  • the invention relates to a process wherein linseed in contacted with water, which optionally contains the desired additives, e.g. inorganic salts and/or flavoring agents, so as to extract polysaccharides from said linseed and separating the aqueous phase containing dissolved polysaccharides from the solid linseed residue.
  • desired additives e.g. inorganic salts and/or flavoring agents
  • the obtained aqueous phase can then be dried, e.g. by lyophilization, to a dry product which is then dissolved in water to be used as the saliva substitute.
  • a dry product which is then dissolved in water to be used as the saliva substitute.
  • the obtained aqueous phase is used directly as said saliva substitute, provided that it has the desired viscosity. If this is not the case, the viscosity can be adjusted by simply adjusting the concentration of the polysaccharide fraction in the aqueous liquid.
  • a sterilization of the solution referred to is performed, which is applicable to both of the above-mentioned alternatives or embodiments.
  • Such a sterilization is performed in a manner known per se, for instance by heating, such as to about 100° C., with a maintenance time of some minutes and then preferably rapid cooling.
  • the proportions or the ratio between liquid (water) and linseed in the extraction is preferably selected, as was previously mentioned, in such a way that the obtained solution containing the dissolved polysaccharides has the desired viscosity per se. Typically this means about 50-150 g, e.g. 100 g, of linseed per liter of liquid.
  • the extraction is typically performed for at least about 3-4 hours.
  • the seeds do not contain any mold which may contain toxins (inter alia allergenic toxins) and preferably the seeds should be rinsed rapidly in order to remove dust, gravel, etc.
  • toxins inter alia allergenic toxins
  • the used linseed does not have to be milled or crushed before the extraction. This means that the residual seeds can be utilized at a linseed extraction.
  • the yield of the polysaccharide fraction is typically of the order of 4 percent by weight (dry weight of polysaccharides) based on the solids content of the linseed. After the drying operation the fraction is essentially lipid free (generally below 1%) and the protein contents thereof is generally lower than 10% (typically 2-9% according to the Kjeldahl analysis).
  • Another aspect of the invention relates to an aqueous solution having the above-mentioned characteristics and for use as a saliva substitute.
  • the saliva substitute according to the invention can be utilized in two ways. Firstly it can of course be utilized merely for rinsing the oral cavity, whereupon it is spitted out again. Thanks to its content of pure natural products and its pleasant taste it may, however, also well be swallowed, the effect thereof being not only a lubricating effect in the mouth and in the pharynx but also an effect throughout the whole gastro intestinal tract.
  • the substitute according to the present invention has a taste of its own which is accepted by man, but of course it is possible, if desired, to add flavoring agents as well as other additives of conventional types.
  • the linseed polysaccharides represent the major constituent of the active ingredient of the saliva substitute, it is also possible to add minor amounts of other previously known saliva substitutes without deviating from the general idea of the present invention.
  • saliva substitute is also utilized as a carrier for pharmaceuticals intended to be taken orally.
  • this use is not limited to some specific pharmaceutical(s) but works for different types of pharmaceuticals intended to be taken orally and with which the present polysaccharides are compatible.
  • interesting pharmaceuticals in this context are, however, analgestics or antibiotics as well as the previously mentioned cortico steroids.
  • this means a preferable and pleasant way of swallowing said pharceutical it is also interesting with reference to an even more continuous distribution of addition of the pharmaceutical with time, i.e. throughout the day and night.
  • still another aspect of the invention relates to the use of a saliva substitute according to the above-mentioned definitions as a carrier for pharmaceuticals for oral applications.
  • Linseed in an amount of 100 g and of the variety Szegedi 62 was added to 1 liter of distilled water and the mixture was mixed throughout 24 hours. The obtained solution was separated from said linseed by centrifugation and was lyophilized.
  • the lyophilized product When used as a saliva substitute the lyophilized product is then stirred into ordinary tap water (of a good quality). A concentration of one percent by weight thereof then gives a viscosity of 280 mPa.s and by a dilution thereof to a concentration of 0.2 percent by weight it works very well as a saliva substitute.
  • composition below from Tadorna linseed, was evaluated as a saliva substitute on a number of patients in the following way.
  • the viscosity was measured to about 30-40 mPa.s.
  • the product was filled on bottles and autoclaved at 100° C. for 2 minutes.
  • the viscosity was measured to 22 mPa.s and the pH was 5.5.
  • the registrations of the plaque index and the gingival index before and after 7 days of use of the composition indicate that the oral hygiene level was somewhat better after the test period.
  • the average index value decreased from 45 % of the tooth surfaces with bacteria deposits before to 23% after the use of the composition.
  • the corresponding values were 18% and 14%, respectively, (table 16).
  • Dryness of the mouth causes a number of local symptoms in the oral cavity, the pharynx and the esophagus.
  • the symptoms may cause disablement to the patient, physically as well as mentally.
  • the aggressiveness and the frequency of the infectious diseases in the oral cavity will increase during xerostomia.
  • the responses of the inquiries seem to indicate that the symptoms as to the pharynx and the esophagus as well as in connection with the upper respiratory tract are as troublesome as those of the oral cavity.
  • Burning tongue seems to be the most pronounced symptom as to the mouth.
  • the composition had a positive influence upon most of the symptoms in connection with xerostomia.
  • the levels of the effect varied from one patient to another. It cannot be precluded that there was some placebo effect.
  • composition had the best effect in patients having great troubles as the consequences of xerostomia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
  • Endoscopes (AREA)
  • Prostheses (AREA)
US07/864,395 1991-04-10 1992-04-06 Saliva substitute Expired - Lifetime US5260282A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9101076-9 1991-04-10
SE9101076A SE9101076L (sv) 1991-04-10 1991-04-10 Saliversaettningsmedel

Publications (1)

Publication Number Publication Date
US5260282A true US5260282A (en) 1993-11-09

Family

ID=20382422

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/864,395 Expired - Lifetime US5260282A (en) 1991-04-10 1992-04-06 Saliva substitute

Country Status (9)

Country Link
US (1) US5260282A (de)
EP (1) EP0511181B1 (de)
JP (1) JPH05112460A (de)
AT (1) ATE108665T1 (de)
CA (1) CA2065530A1 (de)
DE (1) DE69200248T2 (de)
DK (1) DK0511181T3 (de)
ES (1) ES2056703T3 (de)
SE (1) SE9101076L (de)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494665A (en) * 1992-11-02 1996-02-27 Senju Pharmaceutical Co., Ltd. Man-made saliva fluids
US5541165A (en) * 1994-09-27 1996-07-30 Turgeon; Jean A. Saliva substitute
US20040079921A1 (en) * 2000-06-29 2004-04-29 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US20040115248A1 (en) * 2003-11-19 2004-06-17 Fels William F. Compositions and methods relating to hydration of non-human animals
US20060263414A1 (en) * 2005-05-19 2006-11-23 Pauline Pan Confectionery products for the treatment of dry mouth
US20060263306A1 (en) * 2005-05-19 2006-11-23 Pauline Pan Compositions having improved substantivity
US20070264365A1 (en) * 2004-02-05 2007-11-15 Sinclair Pharmaceuticals Ltd Linseed Extract for Xerostomia Treatment
WO2008012548A1 (en) 2006-07-28 2008-01-31 Sinclair Pharmaceuticals Limited Linseed extract medicament for application to the eye
US20090068122A1 (en) * 2007-09-06 2009-03-12 Shira Pilch Dentifrice Compositions for Treating Xerostomia
US9597278B2 (en) 2008-11-13 2017-03-21 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
US9884082B2 (en) 2008-11-13 2018-02-06 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
US10524993B2 (en) 2015-11-19 2020-01-07 Fantarella & Harewood, Llc Mouthwash composition

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2318292A (en) * 1996-09-12 1998-04-22 Simon Everard Barton Saliva-like protectants
JP4804420B2 (ja) * 1999-03-24 2011-11-02 生化学工業株式会社 人工唾液
EP1293131A4 (de) * 2000-06-21 2005-10-19 Kao Corp Mittel zur rachenbehandlung
EP1648405A1 (de) * 2003-05-30 2006-04-26 Isomers Laboratories Inc. Kosmetik mit leinsamenextrakt als trägermittel
GB0504153D0 (en) * 2005-03-01 2005-04-06 Brooks Sarah Annabelle Lubricating composition
RU2362552C1 (ru) * 2008-05-26 2009-07-27 Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия" Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО УГМА Росздрава) Препарат для заместительной терапии при сухости в полости рта

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE676130C (de) * 1938-02-04 1939-05-30 Dr Albert Regensburger Verfahren zur Herstellung eines wohlschmeckenden Abfuehrmittels aus Leinsamen
GB546589A (en) * 1941-01-09 1942-07-20 Lola Hopkins Improvements in medicines
FR2557797A1 (fr) * 1984-01-09 1985-07-12 Cheikho Zahira Composition therapeutique a base de terminalia chebula pour le traitement du psoriasis par voie orale.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE676130C (de) * 1938-02-04 1939-05-30 Dr Albert Regensburger Verfahren zur Herstellung eines wohlschmeckenden Abfuehrmittels aus Leinsamen
GB546589A (en) * 1941-01-09 1942-07-20 Lola Hopkins Improvements in medicines
FR2557797A1 (fr) * 1984-01-09 1985-07-12 Cheikho Zahira Composition therapeutique a base de terminalia chebula pour le traitement du psoriasis par voie orale.

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"A double-blind crossover trial of CMC-and mucin-containing saliva substitutes", by L. L. Visch et al., Int. J. Oral Maxillofac. Surg., vol. 15, pp. 395 to 400 (1986).
"Fish Silage-Influence of Ensiling Conditions on Fat Oxidation" by K. Wannerberger and B. Sivak, Manuscript for publication in Int. J. Food Sci. Technol.
"Functional Role of Linseed (linum usitatissimum L.) Polysaccharide in Steamed Pudding (idli)", by N. S. Susheelamma, J. Fd. Sci. Technol., vol. 26, No. 1, pp. 16 to 20 (1989).
"Rheological and Chemical Properties of Mucilage in Different Varieties from Linseed (Linum usitatissimum)", by K. Wannerberger et al, Acta Agr. Scand., vol. 41, pp. 311 to 319 (1991).
"Rheological and Chemical Properties of Mucilage in Different Varieties from Linseed" (Linum usitatissimum) by K. Wannerberger, T. Nylander and M. Nyman, Manuscript for publication.
"Unconventional Sources for Food and Feed-Studies on Linseed Mucilage and Fish Silage" (1990) by Kirstin Wannerberger from Food Technology series, the University of Lund.
"Vlastnosti l'Anovecho Mucinu. VII.*) Charakteristika niektorych z purifikovaneho produktu", vol. 19, No. 4, pp. 143 to 146 (1970).
A double blind crossover trial of CMC and mucin containing saliva substitutes , by L. L. Visch et al., Int. J. Oral Maxillofac. Surg., vol. 15, pp. 395 to 400 (1986). *
Fish Silage Influence of Ensiling Conditions on Fat Oxidation by K. Wannerberger and B. Sivak, Manuscript for publication in Int. J. Food Sci. Technol. *
Functional Role of Linseed (linum usitatissimum L.) Polysaccharide in Steamed Pudding (idli) , by N. S. Susheelamma, J. Fd. Sci. Technol., vol. 26, No. 1, pp. 16 to 20 (1989). *
Rheological and Chemical Properties of Mucilage in Different Varieties from Linseed ( Linum usitatissimum ) by K. Wannerberger, T. Nylander and M. Nyman, Manuscript for publication. *
Rheological and Chemical Properties of Mucilage in Different Varieties from Linseed (Linum usitatissimum) , by K. Wannerberger et al, Acta Agr. Scand., vol. 41, pp. 311 to 319 (1991). *
Unconventional Sources for Food and Feed Studies on Linseed Mucilage and Fish Silage (1990) by Kirstin Wannerberger from Food Technology series, the University of Lund. *
Vlastnosti l Anov cho Muc nu. VII.*) Charakteristika niektorych z purifikovan ho produktu , vol. 19, No. 4, pp. 143 to 146 (1970). *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494665A (en) * 1992-11-02 1996-02-27 Senju Pharmaceutical Co., Ltd. Man-made saliva fluids
US5541165A (en) * 1994-09-27 1996-07-30 Turgeon; Jean A. Saliva substitute
US20040079921A1 (en) * 2000-06-29 2004-04-29 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US6773627B2 (en) 2000-06-29 2004-08-10 Children's Hospital Research Foundation Cubic liquid crystalline compositions and methods for their preparation
US20040115248A1 (en) * 2003-11-19 2004-06-17 Fels William F. Compositions and methods relating to hydration of non-human animals
US20070264365A1 (en) * 2004-02-05 2007-11-15 Sinclair Pharmaceuticals Ltd Linseed Extract for Xerostomia Treatment
US20100202981A1 (en) * 2005-05-19 2010-08-12 Pauline Pan Compositions having improved substantivity
US20060263414A1 (en) * 2005-05-19 2006-11-23 Pauline Pan Confectionery products for the treatment of dry mouth
US20060263306A1 (en) * 2005-05-19 2006-11-23 Pauline Pan Compositions having improved substantivity
WO2008012548A1 (en) 2006-07-28 2008-01-31 Sinclair Pharmaceuticals Limited Linseed extract medicament for application to the eye
US20090068122A1 (en) * 2007-09-06 2009-03-12 Shira Pilch Dentifrice Compositions for Treating Xerostomia
US9597278B2 (en) 2008-11-13 2017-03-21 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
US9884082B2 (en) 2008-11-13 2018-02-06 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
US10201582B2 (en) 2008-11-13 2019-02-12 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
US10524993B2 (en) 2015-11-19 2020-01-07 Fantarella & Harewood, Llc Mouthwash composition
US11318078B2 (en) 2015-11-19 2022-05-03 Fantarella & Harewood, Llc Mouthwash composition

Also Published As

Publication number Publication date
EP0511181A1 (de) 1992-10-28
ATE108665T1 (de) 1994-08-15
SE9101076L (sv) 1992-10-11
DE69200248D1 (de) 1994-08-25
CA2065530A1 (en) 1992-10-11
DE69200248T2 (de) 1994-10-27
EP0511181B1 (de) 1994-07-20
ES2056703T3 (es) 1994-10-01
JPH05112460A (ja) 1993-05-07
SE9101076D0 (sv) 1991-04-10
DK0511181T3 (da) 1994-09-12

Similar Documents

Publication Publication Date Title
US5260282A (en) Saliva substitute
CA2545626C (en) Sialogogue, oral composition and food product containing the same
KR101955468B1 (ko) 천연 추출물을 함유하는 치약 조성물의 제조방법
JPH0952835A (ja) 経口薬剤構成物
US20080069783A1 (en) Oral cavity cleaning composition
CN112426376B (zh) 一种漱口水及其制备方法
CN110946778A (zh) 一种具有消炎抑菌作用的牙膏
JP5754711B2 (ja) 唾液分泌の促進に有効な口腔衛生組成物、および、口腔ケア製品
JP2021065176A (ja) 口腔内病原性細菌の生育抑制剤、口腔用組成物及び促進剤
JP2003081800A (ja) 抗歯周病剤
CN106729649B (zh) 一种治疗口干症的口腔护理组合物及其应用
KR101293645B1 (ko) 신장염 예방 또는 치료용 약학 조성물
JP3008138B2 (ja) グアーガム酵素分解物を有効成分とする腸内環境改善剤
KR20080087941A (ko) 저분자량 히알우론산을 함유하는 피부주름개선 및각질제거용 조성물
RU2095052C1 (ru) Состав для профилактики заболеваний пародонта
JP3140412B2 (ja) 牛膝または楡白皮抽出物を含有する口腔用組成物
JP6218280B2 (ja) 唾液分泌促進剤
KR101458670B1 (ko) 분지쇄아미노산을 함유하는 약제학적 조성물 및 그 제조방법
JP2007269805A (ja) 人工唾液
CN107613999A (zh) 唾液分泌促进剂、口腔干燥抑制剂及口腔内湿润赋予剂、及组合物
EP3714940A1 (de) Pharmazeutische formulierung zur oralen anwendung, die honig und pflanzenextrakte mit einem getesteten polysaccharid- und schleimgehalt enthält, zur behandlung von produktivem und nicht-produktivem husten und halserkrankungen
KR101475594B1 (ko) 용뇌 및 죽염을 포함하는 구강 조성물
WO2024153892A1 (fr) Composition pour l'hygiene bucco-dentaire
WO2022248533A1 (fr) Compositions de soins bucco-dentaires
KR20000060218A (ko) 노박덩굴 추출물을 함유한 구강조성물

Legal Events

Date Code Title Description
AS Assignment

Owner name: CAMURUS AB, A CORPORATION OF SWEDEN, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:ATTSTROM, ROLF;GLANTZ, PER-OLOF;HAKANSSON, HAKAN;AND OTHERS;REEL/FRAME:006097/0052;SIGNING DATES FROM 19920313 TO 19920318

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: GS DEVELOPMENT AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CAMURUS AB;REEL/FRAME:008489/0909

Effective date: 19970218

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12